Palobiofarma starts clinical trials on the first adenosine-based drug developed in Spain for the treatment of Parkinsonʼs disease
Palobiofama, SL, a biotechnology company located at the Barcelona Science Park, has started clinical trials of its first drug, the compound PBF-509, a potent antagonist of the adenosine A2a receptors. The drug, discovered, developed, and patented entirely by Palobiofarma, is a very innovative treatment that aims to improve movement and cognitive disorders in patients who suffer Parkinson's disease. In order to treat this disease there are only drugs with a palliative effect.
Palobiofama, SL, a biotechnology company located at the Barcelona Science Park, has started clinical trials of its first drug, the compound PBF-509, a potent antagonist of the adenosine A2a receptors. The drug, discovered, developed, and patented entirely by Palobiofarma, is a very innovative treatment that aims to improve movement and cognitive disorders in patients who suffer Parkinson's disease. In order to treat this disease there are only drugs with a palliative effect.
More information on this link